We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA has fired off warning letters to two supplement makers over GMP concerns ranging from record handling to incomplete batch production records. Read More
As pharmacy benefit managers’ exclusion lists grow longer, drug developers hoping to avoid those lists must scramble to demonstrate clinical superiority and cost-effectiveness of their products, according to a new report. Read More
While three newer treatment options for multiple myeloma appear to improve patient survival and quality of life, their costs exceed their value, according to a new report. Read More
Several days after Valeant Pharmaceuticals International executives pledged to establish a committee to review its drug pricing practices, the Senate Aging Committee released a treasure trove of documents related to the company’s internal pricing strategies. Read More
The UK’s drug pricing watchdog seems to have warmed to AbbVie’s Humira, recommending the drug be covered four months after one of its committees proposed rejecting it. Read More